Navigation Links
Spherix to Effect Reverse Stock Split
Date:4/19/2011

ceuticals, medical devices, consumer products and industrial chemicals and pesticides. For more information, please visit www.spherix.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of D-tagatose, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our continuing efforts to develop D-tagatose may be unsuccessful, our common stock could be delisted from the Nasdaq Capital Market, and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our current report on Form 8-K filed on October 10, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Spherix Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Spherix Announces 2010 Financial Results
2. Spherix to Present at the BIO-Windhover/Pharmaceutical Strategic Outlook 2011 Conference
3. Spherix to Present at the 13th Annual BIO CEO & Investor Conference
4. Spherix Announces Closing of Registered Direct Offering of $2.77 Million in Common Stock and Warrants
5. Spherix to Present at Two Upcoming Prominent Finance Conferences
6. Spherix Phase 2 Trial with D-tagatose Determines Minimum Dose for HbA1c and Triglycerides
7. Spherix Signs Research Contract With a Leading Global Contract Research Organization to Investigate Role of D-tagatose in Lowering Triglycerides
8. Spherix to Hold Business Update Conference Call December 9, 2010 at 4:30 p.m. Eastern Time
9. Spherix Announces Closing of Institutional Investors Purchase of $5.25 Million of Convertible Preferred Stock and Warrants
10. Spherix Announces Statistically Significant Results in Phase 3 Study With D-tagatose in Type 2 Diabetes
11. Spherix Announces Second Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 /PRNewswire/ - RepliCel Life ... regenerative medicine company focused on the development of ... the quarter ended June 30, 2015, corporate highlights, ... management report are available at www.sedar.com ,  ... "RepliCel expects to launch its ...
(Date:8/28/2015)... , ... August 28, 2015 , ... Since the initial launch of FireflySci Inc. (FFS) ... humor and excellent customer service. Images such as the Fonz in a lab coat ... some flavor to the humdrum spectroscopy field. , FireflySci is proud to be ...
(Date:8/27/2015)... VA (PRWEB) , ... August 27, 2015 , ... ... contractors solve complex business problems, is pleased to announce their ranking as one of ... annual ranking of the fastest-growing private companies across the nation. , “It is truly ...
(Date:8/27/2015)... 27, 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") ... Biohaven Pharmaceutical Holding Company Limited (Biohaven), announced today ... study of BHV-0223, a glutamate modulating agent. Biohaven ... and recently obtained clearance from the U.S. Food ... testing. Portage holds 54% equity interest in Biohaven, ...
Breaking Biology Technology:RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4
... ... Issues of Food and Drug Safety , ... Rockville, Md. (Vocus) September 29, 2009 -- Counterfeit and adulterated food and drugs ... Annual Scientific Meeting (ASM) hosted by the U.S. Pharmacopeial (USP) Convention. Held in Toronto, Canada, ...
... on science especially emerging technologies such as nanotechnology ... science policy released today argues. The group of leading ... that current governance activities are limiting public debate and ... DEEPEN report comes in the wake of a move ...
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ... by Prof. Hardev Pandha of the Royal Surrey County ... online version of Clinical Cancer Research. The paper is ... in Murine Malignant Melanoma." , The research demonstrated that ...
Cached Biology Technology:Global Public Health the Focus of Scientific Conference 2Global Public Health the Focus of Scientific Conference 3Public must be involved in nanotech policy debate demands groundbreaking 2Oncolytics Biotech(R) Inc. Announces Reovirus and Cisplatin Research Supports U.S. Phase 2 Metastatic Melanoma Trial 2
(Date:8/12/2015)... MINNETONKA, Minn. , Aug. 12, 2015   ... that supports the entire spectrum of clinical research, is ... ™ , the company,s comprehensive SaaS-based eClinical technology platform, ... growth during the first two quarters of 2015.   ... and second largest quarters measured by contract value sold ...
(Date:8/12/2015)... JOSE, Calif. , Aug. 12, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that ... recently announced Match-in-Sensor solution, have officially been named ... Alliance. As part of the certification, Synaptics, Natural ... FIDO 1.0 Universal Authentication Framework (UAF) standard and ...
(Date:8/10/2015)... LONDON , August 10, 2015 ... visiongain offers comprehensive analysis of the global border ... will generate revenues of $16.4bn in 2015. Now: ... This is an example of the business critical issue you ... to read visiongain ,s objective analysis of how this ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 4Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 5Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 7Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 8Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 9
... New Rochelle, NY, June 28, 2013 Mary Ann Liebert, ... Printing and Additive Manufacturing , a highly innovative, peer-reviewed ... issue will publish in the fall of 2013, and ... the Director of Cornell University,s Creative Machines Lab at ...
... The world,s food supply got a little more plentiful thanks ... plant pathology at Kansas State University, and his colleague, Jorge ... that identified a gene that gives wheat plants resistance to ... rust pathogen -- called Ug99 -- that was first discovered ...
... 28 2013) A study carried out in India examining ... marrow stem cells in patients with type 2 diabetes ... compared to a control group of TD2M patients who ... The study appears as an early e-publication for the ...
Cached Biology News:Resistance gene found against Ug99 wheat stem rust pathogen 2Resistance gene found against Ug99 wheat stem rust pathogen 3Type 2 diabetes patients transplanted with own bone marrow stem cells reduces insulin use 2
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
... Immunogen: Fusion protein derived from ... ASIP/PAR-3 (atypical PKC isotype-specific interacting protein/ ... not related to the protease-activated-receptors also ... Xenopus (positive controls: Caco-2 MDCK A6 ...
... C-1-tetrahydrofolate synthase, ... [Includes: Methylenetetrahydrofolate dehydrogenase ... cyclohydrolase (EC 3.5.4.9); ... 6.3.4.3)]. [Source:Uniprot/SWISSPROT;Acc:P11586] ...
...
Biology Products: